MAP2K7 and lung carcinoma: In line with this, here we show that genetic ablation of UHRF1 in combination with pharmacological inhibition of KRAS G12C, MEK, or PI3K results in a synergistically anti-proliferative effect in KRAS mutant lung cancer cells in vitro.